News

Video

Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

Author(s):

Ulka Vaishampayan, MD,Alan Tan, MD

Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.

Related Videos
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Stephanie Graff, MD, and Chandler Park, FACP
Elias Jabbour, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Shubham Pant, MD, MBBS
Douglas W. Sborov, MD, MS
Chad Tang, MD
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Chad Tang MD, MD Anderson
Bora Lim, MD, MD Anderson
Related Content
Michael Wang, MD
December 18th 2024

Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

Elias Jabbour, MD, a professor in the Department of Leukemia, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center in Houston
December 6th 2024

ALL Treatment Paradigm Displays Significant Gains as NCCN Guidelines Evolve

Guillermo Garcia-Manero, MD, professor, chief, section of Myelodysplastic Syndromes, deputy chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
August 19th 2024

Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond

ALLO-316 in Advanced CD70-Positive ccRCC | Image Credit: © Cornflakesei - stock.adobe.com
November 27th 2024

ALLO-316 Demonstrates Early Activity and Safety in Advanced CD70-Positive ccRCC

Chelsey Schlechter, MPH, PhD
November 27th 2024

Dr Schlechter Named Cancer Moonshot Scholar